Organon Pharmaceuticals Usa Inc. Sustainability Profile
Organon Pharmaceuticals USA Inc., a prominent player in the global healthcare landscape, is headquartered in the United States. Founded in 2021, the company emerged as a spin-off from Merck & Co., focusing on women's health, biosimilars, and other therapeutic areas. With a commitment to advancing healthcare solutions, Organon offers a diverse portfolio of products, including contraceptives and hormone therapies, distinguished by their innovative formulations and patient-centric approach. Operating primarily in North America and expanding into international markets, Organon has quickly established itself as a leader in women's health. The company’s dedication to addressing unmet medical needs has garnered recognition, positioning it as a trusted partner in the pharmaceutical industry. With a strong emphasis on research and development, Organon continues to make significant strides in improving health outcomes for women worldwide.
DitchCarbon Score
How does Organon Pharmaceuticals Usa Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon Pharmaceuticals Usa Inc.'s score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon Pharmaceuticals USA Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Merck & Co., Inc., any emissions data or climate commitments may be inherited from its parent company. Merck & Co., Inc. has established various climate initiatives, including Science-Based Targets Initiative (SBTi) commitments, which are cascaded to Organon. However, specific reduction targets or achievements for Organon itself are not detailed. The company is part of a broader industry context that increasingly prioritises sustainability and carbon reduction, yet specific metrics or commitments from Organon Pharmaceuticals USA Inc. remain unspecified at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,532,400,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Organon Pharmaceuticals Usa Inc.'s Industry?
How Carbon Intensive is Organon Pharmaceuticals Usa Inc.'s Location?
Organon Pharmaceuticals Usa Inc.'s Scope 3 Categories Breakdown
Organon Pharmaceuticals Usa Inc.'s Scope 3 emissions, which increased by 3% last year and increased by approximately 5% since 2014, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Organon Pharmaceuticals Usa Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Organon Pharmaceuticals Usa Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
